Beneficial Ownership Report · SCHEDULE 13G
TherapeuticsMD, Inc.
TXMDNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G
primary_doc.xml
Subject company
- Company
- TherapeuticsMD, Inc.
- Company CIK
- 0000025743
- Street
- 951 Yamato Road, Suite 220
- City
- Boca Raton
- State / country code
- FL
- Postal code
- 33431
Statement details
- Security class
- Common Stock, par value $0.001 per share
- Event date
- 03/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Baselake Partners, LP
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- b
- Aggregate amount owned
- 607,181.00
- Percent of class
- 5.2
- Sole voting power
- 0.00
- Shared voting power
- 607,181.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 607,181.00
- Aggregate excludes certain shares
- N
- Comments
- Please see note in Item 4(a)
Reporting person 2
- Name
- Baselake Management, LLC
- Citizenship / organization
- DE
- Reporting person type
- IA · OO
- Group designation
- b
- Aggregate amount owned
- 607,181.00
- Percent of class
- 5.2
- Sole voting power
- 0.00
- Shared voting power
- 607,181.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 607,181.00
- Aggregate excludes certain shares
- N
- Comments
- Please see note in Item 4(a)
Reporting person 3
- Name
- David Paolella
- Citizenship / organization
- X1
- Reporting person type
- HC · IN
- Group designation
- b
- Aggregate amount owned
- 607,181.00
- Percent of class
- 5.2
- Sole voting power
- 0.00
- Shared voting power
- 607,181.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 607,181.00
- Aggregate excludes certain shares
- N
- Comments
- Please see note in Item 4(a)
Item 1
Issuer
TherapeuticsMD, Inc.
Principal executive office address
951 Yamato Road, Suite 220 Boca Raton, Florida 33431
Item 2
Citizenship
Baselake Partners, LP - Delaware Baselake Management, LLC - Delaware David Paolella - United States of America
Filing person
Baselake Partners, LP* Baselake Management, LLC* David Paolella*
Principal business or residence address
3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084
Item 3
Not applicable indication
Y
Item 4
Percent of class
Baselake Partners, LP - 5.2%* Baselake Management, LLC - 5.2%* David Paolella - 5.2%*
Amount beneficially owned
Baselake Partners, LP - 607,181* Baselake Management, LLC - 607,181* David Paolella - 607,181* The Common Stock (the "Shares") reported as of the filing date are held by Baselake Partners, LP (the "Fund"). Baselake Management, LLC serves as the investment manager to the Fund (the "Investment Manager"). David Paolella serves as the managing member of the Investment Manager (the "Managing Member," and collectively with the Fund and the Investment Manager, the "Reporting Persons"). By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Fund. The percentages reported herein are calculated based upon a statement in the Issuer's 10-K, indicating that there are 11,574,362 Shares issued and outstanding as of March 30, 2026. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein.
Sole voting power
Baselake Partners, LP - 0 Baselake Management, LLC - 0 David Paolella - 0
Shared voting power
Baselake Partners, LP - 607,181* Baselake Management, LLC - 607,181* David Paolella - 607,181*
Sole dispositive power
Baselake Partners, LP - 0 Baselake Management, LLC - 0 David Paolella - 0
Shared dispositive power
Baselake Partners, LP - 607,181* Baselake Management, LLC - 607,181* David Paolella - 607,181*
Item 5
Not applicable indication
Y
Item 6
Not applicable indication
Y
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
Signature comments
Exhibit I - JOINT FILING STATEMENT
Signature 1
- Reporting person
- Baselake Partners, LP
- Signed
- /s/ David Paolella
- Title
- David Paolella, Managing Member of Baselake Management, LLC, its investment manager
- Date
- 04/06/2026
Signature 2
- Reporting person
- Baselake Management, LLC
- Signed
- /s/ David Paolella
- Title
- David Paolella, Managing Member
- Date
- 04/06/2026
Signature 3
- Reporting person
- David Paolella
- Signed
- /s/ David Paolella
- Title
- Individually
- Date
- 04/06/2026
Filed exhibits
- EX-1 ↗ex1.htm
Company context
TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations.
Current securities
Recent company filings
- 10-Q filingAug 11, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 11, 2026
- SCHEDULE 13G/A - filed by Baselake Partners, LP regarding TherapeuticsMD, Inc.Aug 5, 2026
- 10-Q filingMay 12, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureMay 12, 2026